Literature DB >> 26997307

Personalized medicine in neuro-oncology.

Victor A Levin1,2,3.   

Abstract

Keywords:  biomarkers; chemotherapy; genetics; glioblastoma; glioma

Mesh：

Year:  2016        PMID： 26997307      PMCID： PMC6047424          DOI： 10.2217/cns-2016-0006

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  40 in total

1.  Personalized cancer care: opportunities and challenges in pediatric neuro-oncology.

Authors:  Lara E Davis; Motomi Mori; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2011-12-09       Impact factor: 3.167

2.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Authors:  Roger E McLendon; James E Herndon; Bryan West; David Reardon; Rodney Wiltshire; B K Ahmed Rasheed; Jennifer Quinn; Henry S Friedman; Allan H Friedman; Darell D Bigner
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

Review 4.  Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Authors:  Monique P Curran
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

5.  Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas.

Authors:  Matthias Holdhoff; Xiaobu Ye; Jaishri O Blakeley; Lindsay Blair; Peter C Burger; Stuart A Grossman; Luis A Diaz
Journal:  J Neurooncol       Date:  2012-08-29       Impact factor: 4.130

6.  A multigene predictor of outcome in glioblastoma.

Authors:  Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

Review 7.  Glioma biology and molecular markers.

Authors:  Adam L Cohen; Howard Colman
Journal:  Cancer Treat Res       Date:  2015

8.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

9.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

10.  Do firms underinvest in long-term research? Evidence from cancer clinical trials.

Authors:  Eric Budish; Benjamin N Roin; Heidi Williams
Journal:  Am Econ Rev       Date:  2015-07
View more
  1 in total

1.  N-(p-coumaroyl) serotonin inhibits glioblastoma cells growth through triggering S-phase arrest and apoptosis.

Authors:  Diamanto Lazari; George A Alexiou; Georgios S Markopoulos; Evrysthenis Vartholomatos; Entela Hodaj; Ieremias Chousidis; Ioannis Leonardos; Vasiliki Galani; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2017-04-01       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.